Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer announced that its once-daily drug LITFULO (ritlecitinib) demonstrated significant improvements in facial and total body repigmentation compared to a placebo in two Phase 3 trials for nonsegmental vitiligo. The company plans to submit for regulatory approval in the US and EU.
Pfizer said it will present data from 45 company-sponsored, investigator-sponsored and collaborative research abstracts at the European Society for Medical Oncology congress in Madrid, Spain, on Oct. 23-27, 2026.
PFE Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Pfizer announces topline Phase 3 results for Sigvotatug Vedotin in previously treated metastatic non-squamous non-small cell lung cancer